When talking with emergency room doctors about chest pain, patient risks for acute coronary syndromes aren’t being conveyed. According a study published online March 4 in Annals of Emergency Medicine, even after talking to their doctor, patient estimates for MI mortality risks were hugely overestimated.

There’s a lot to see at ACC.15. Here are some cutting-edge technologies you’ll want to check out.

Just one day after making their MyHeart Counts app publicly available, researchers at Stanford University School of Medicine found 11,000 people had enrolled in their iPhone-enabled cardiovascular study.

The public and participants of clinical trials are finding results hard to come by. Research into trial reporting found that despite legal requirements, results are not being promptly disseminated through ClinicalTrials.gov.

A study published in the March 10 issue of JAMA may help unravel the possible relationship between statin use and the increased risk of diabetes. If confirmed, the findings may provide a pathway for new treatments. 

Agfa HealthCare announced today the commercial launch of its Enterprise Imaging for Cardiology Suite and strategic relationship with TomTec to provide a unified cardiology diagnostic and clinical imaging solution. The solution will be on display at the American College of Cardiology (ACC) 2015 Scientific Session & Expo, March 14-16, 2015 in San Diego.

Sanofi and Regeneron Pharmaceuticals, Inc. will present Phase 3 data from the PraluentTM (alirocumab) clinical program at the American College of Cardiology’s 64th Annual Scientific Session & Expo (ACC.15), being held March 14-16 in San Diego. Data includes detailed results from two new Phase 3 trials evaluating monthly dosing of Praluent in patients with hypercholesterolemia, as well as pooled safety analyses of up to nine Praluent trials.

Integrating new technology into everyday peripheral artery disease (PAD) practice may become a case of following the heart, or at least the coronaries.